HUP0401434A2 - Szulfonált mezo-tetrafenil-klorint tartalmazó fényérzékenyítő szer, eljárás az előállítására és ezt tartalmazó gyógyszerkészítmények - Google Patents

Szulfonált mezo-tetrafenil-klorint tartalmazó fényérzékenyítő szer, eljárás az előállítására és ezt tartalmazó gyógyszerkészítmények

Info

Publication number
HUP0401434A2
HUP0401434A2 HU0401434A HUP0401434A HUP0401434A2 HU P0401434 A2 HUP0401434 A2 HU P0401434A2 HU 0401434 A HU0401434 A HU 0401434A HU P0401434 A HUP0401434 A HU P0401434A HU P0401434 A2 HUP0401434 A2 HU P0401434A2
Authority
HU
Hungary
Prior art keywords
meso
phenylporphyrin
tetra
preparation
pharmaceutical compositions
Prior art date
Application number
HU0401434A
Other languages
English (en)
Inventor
Claude Rimington
Kristian Berg
Diem Tran
Pal Kristian Selbo
Original Assignee
Pci Biotech As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pci Biotech As filed Critical Pci Biotech As
Publication of HUP0401434A2 publication Critical patent/HUP0401434A2/hu
Publication of HUP0401434A3 publication Critical patent/HUP0401434A3/hu
Publication of HU229623B1 publication Critical patent/HU229623B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/008—Two-Photon or Multi-Photon PDT, e.g. with upconverting dyes or photosensitisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Detergent Compositions (AREA)
  • Photoreceptors In Electrophotography (AREA)

Abstract

%-5> A találmány egy szulfonált mezo-tetrafenilporfirin, előnyösendiszulfonált mezo-tetrafenilporfirin, például TPPS2a porfirin-makrociklusában lévő egyetlen kettőskötés redukálásával előállítottfényérzékenyítő anyagokra vonatkozik. A képződő szulfonált mezo-tetrafenilklorinok például olyan (I) általános képletű vegyületek,amelyek képletében X jelentése -SO3H képletű csoport; n, p, q és rértéke 0 vagy l; és n, p, q és r értékének összege 1 és 4 közöttiegész szám, előnyösen legalább 2, például 2 vagy 4, vagy ezek izomereivagy izomereinek keverékei. A találmány szerinti vegyületek és ezekgyógyászatilag elfogadható sói különösen jól alkalmazhatók molekulákfotokémiai bevitelére és fotodinamikus terápiában fényérzékenyítőanyagként. Ó
HU0401434A 2001-08-30 2002-08-30 Photosensitizing agent containing sulphonated meso-tetra-phenylporphyrin HU229623B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0121023.6A GB0121023D0 (en) 2001-08-30 2001-08-30 Compound
PCT/GB2002/003973 WO2003020309A2 (en) 2001-08-30 2002-08-30 Compound

Publications (3)

Publication Number Publication Date
HUP0401434A2 true HUP0401434A2 (hu) 2004-12-28
HUP0401434A3 HUP0401434A3 (en) 2008-05-28
HU229623B1 HU229623B1 (en) 2014-03-28

Family

ID=9921225

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0401434A HU229623B1 (en) 2001-08-30 2002-08-30 Photosensitizing agent containing sulphonated meso-tetra-phenylporphyrin

Country Status (20)

Country Link
US (2) US7662807B2 (hu)
EP (1) EP1420824B1 (hu)
JP (1) JP5068920B2 (hu)
KR (1) KR100883927B1 (hu)
CN (1) CN100438909C (hu)
AT (1) ATE327768T1 (hu)
BR (1) BRPI0212172B8 (hu)
CA (1) CA2457856C (hu)
DE (1) DE60211918T2 (hu)
ES (1) ES2265047T3 (hu)
GB (1) GB0121023D0 (hu)
HK (1) HK1060974A1 (hu)
HU (1) HU229623B1 (hu)
MX (1) MXPA04001813A (hu)
NO (1) NO332191B1 (hu)
NZ (1) NZ531598A (hu)
PL (1) PL206900B1 (hu)
PT (1) PT1420824E (hu)
RU (1) RU2323940C2 (hu)
WO (1) WO2003020309A2 (hu)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0415263D0 (en) * 2004-07-07 2004-08-11 Norwegian Radium Hospital Res Method
FR2877943B1 (fr) * 2004-11-16 2008-09-05 Univ De Coimbra Nouveaux derives de porphyrine, notamment chlorines et/ou bacteriochlorine, et leurs applications en therapie photodynamique
CN100361994C (zh) * 2004-12-10 2008-01-16 吉林大学 四苯基卟啉衍生物及其在有机电致发光器件中的应用
GB0613753D0 (en) 2006-07-11 2006-08-23 Norwegian Radium Hospital Res Method
CN101153085B (zh) * 2006-09-25 2010-05-12 中国科学院化学研究所 具有可逆手性的超分子手性膜及其制备方法
WO2008102669A1 (ja) * 2007-02-19 2008-08-28 Rei Medical Co., Ltd. 新規な糖連結クロリン誘導体及びその製造方法
GB0811955D0 (en) 2008-06-30 2008-07-30 Pci Biotech As Method
KR100972504B1 (ko) * 2008-07-14 2010-07-26 김현종 휴대가 가능한 접철식 노트북 받침대
CN102159569B (zh) * 2008-09-18 2016-02-03 拜莱泰克制药市场有限公司 用于pdt的不对称内消旋取代的卟啉和二氢卟酚及其应用
GB0819594D0 (en) 2008-10-24 2008-12-03 Univ Coimbrra Process
GB0914286D0 (en) * 2009-08-14 2009-09-30 Pci Biotech As Method
GB0914287D0 (en) * 2009-08-14 2009-09-30 Pci Biotech As Compositions
CN102260269B (zh) * 2010-05-25 2013-11-06 苏州和健医药科技有限公司 一种含有卟啉或二氢卟吩的树状化合物及其应用
CN102653541B (zh) * 2011-03-04 2014-01-15 国家纳米科学中心 一种卟啉化合物及其制备方法和应用
CN102786526B (zh) * 2011-05-20 2014-07-16 国家纳米科学中心 一种卟啉-酞菁二连体及其制备方法和应用
US8907081B2 (en) 2011-05-27 2014-12-09 Sharp Laboratories Of America, Inc. Long wavelength absorbing porphyrin photosensitizers for dye-sensitized solar cells
GB201208548D0 (en) 2012-05-15 2012-06-27 Pci Biotech As Compound and method
CN102952143B (zh) * 2012-11-08 2015-12-02 唐江涛 一种四苯基卟吩的制备方法
CA2906279A1 (en) * 2013-03-15 2014-09-18 Pci Biotech As A method of generating antigen presenting cells using photochemical internalisation
EP3038619B1 (en) 2013-08-28 2023-10-04 PCI Biotech AS Compound and method for vaccination and immunisation
WO2015028575A1 (en) * 2013-08-28 2015-03-05 Pci Biotech As Immunisation method by photochemical internalisation
AU2015308345B9 (en) 2014-08-28 2020-12-24 Pci Biotech As Compound and method
CN104459099B (zh) * 2014-12-18 2016-04-13 东南大学 卟啉衍生物在制备检测炎症相关疾病试剂中的应用
GB201503776D0 (en) 2015-03-05 2015-04-22 Pci Biotech As Compound and method
RU2019109682A (ru) 2016-10-14 2020-11-16 ПиСиАй БИОТЕК АС Лечение холангиокарциномы с применением tpcs-2-индуцированной фотохимической интернализации гемцитабина
GB201718631D0 (en) 2017-11-10 2017-12-27 Pci Biotech As Method
EP3823668A1 (en) 2018-07-16 2021-05-26 DCPrime B.V. A combination product for use in tumor vaccination
WO2020217226A1 (en) 2019-04-25 2020-10-29 Dcprime B.V. Methods of tumor vaccination
CN112898310A (zh) * 2019-12-03 2021-06-04 中国石油天然气股份有限公司 地质卟啉加氢衍生化方法、所得加氢产物及同位素分析法
CN115916963A (zh) 2020-03-27 2023-04-04 门德斯有限公司 白血病来源的经修饰细胞用于增强过继性细胞治疗的效力的离体用途
EP4125943A1 (en) 2020-03-27 2023-02-08 Mendus B.V. In vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
JP2023547520A (ja) 2020-11-05 2023-11-10 メンドゥス・ベスローテン・フェンノートシャップ 免疫療法における腫瘍非依存性抗原の使用
AU2022235341A1 (en) 2021-03-12 2023-09-21 Mendus B.V. Methods of vaccination and use of cd47 blockade

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU204856B (en) 1987-08-12 1992-02-28 Orszagos Mueszaki Fejlesztesi Process for releasing cell mixtures and tissues from undesired populations and for producing monoclonal antibody - hematoporphyrin conjugates
JPH05253466A (ja) * 1992-03-12 1993-10-05 Res Dev Corp Of Japan 磁気異方性薄膜の製造方法
NO180167C (no) 1994-09-08 1997-02-26 Photocure As Fotokjemisk fremgangsmåte til å innföre molekyler i cellers cytosol
GB9700396D0 (en) 1997-01-10 1997-02-26 Photocure As Photochemotherapeutic compositions
JP2000007693A (ja) * 1998-06-26 2000-01-11 Lederle Japan Ltd クロリン誘導体
GB9905911D0 (en) 1999-03-15 1999-05-05 Photocure As Method
AU4139600A (en) * 1999-04-14 2000-11-14 University Of British Columbia, The 1,3-dipolar cycloadditions to polypyrrolic macrocycles

Also Published As

Publication number Publication date
CN100438909C (zh) 2008-12-03
ATE327768T1 (de) 2006-06-15
RU2004109228A (ru) 2005-04-10
WO2003020309A3 (en) 2003-10-30
DE60211918D1 (en) 2006-07-06
NZ531598A (en) 2005-09-30
JP5068920B2 (ja) 2012-11-07
KR100883927B1 (ko) 2009-02-18
MXPA04001813A (es) 2005-03-07
BRPI0212172A8 (pt) 2018-12-18
HK1060974A1 (en) 2004-09-03
JP2005507383A (ja) 2005-03-17
RU2323940C2 (ru) 2008-05-10
NO332191B1 (no) 2012-07-23
BRPI0212172B1 (pt) 2019-03-06
CA2457856C (en) 2011-01-25
CN1549729A (zh) 2004-11-24
US8096419B2 (en) 2012-01-17
BR0212172A (pt) 2004-07-20
WO2003020309A2 (en) 2003-03-13
EP1420824A2 (en) 2004-05-26
KR20040032983A (ko) 2004-04-17
US7662807B2 (en) 2010-02-16
US20060052433A1 (en) 2006-03-09
NO20040822L (no) 2004-04-29
AU2002313562B2 (en) 2006-09-07
PT1420824E (pt) 2006-08-31
GB0121023D0 (en) 2001-10-24
CA2457856A1 (en) 2003-03-13
HUP0401434A3 (en) 2008-05-28
BRPI0212172B8 (pt) 2021-05-25
ES2265047T3 (es) 2007-02-01
DE60211918T2 (de) 2007-01-18
EP1420824B1 (en) 2006-05-31
US20100121255A1 (en) 2010-05-13
HU229623B1 (en) 2014-03-28
PL206900B1 (pl) 2010-10-29
PL369289A1 (en) 2005-04-18

Similar Documents

Publication Publication Date Title
HUP0401434A2 (hu) Szulfonált mezo-tetrafenil-klorint tartalmazó fényérzékenyítő szer, eljárás az előállítására és ezt tartalmazó gyógyszerkészítmények
CA2258548A1 (en) Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
TR200003478T2 (tr) Antikanser maddeleri olarak faydalı izotiyazol türevleri
UY27368A1 (es) Nuevos compuestos
HUP0101999A2 (hu) 4-Hidroxi-kinolin-3-karboxamid- és -hidrazid-származékok, ezeket tartalmazó gyógyászati készítmények, valamint e vegyületek alkalmazása
BR0213612A (pt) Composto, composição farmacêutica, uso do composto e método para tratamento de doença ou condição
AU8794291A (en) New oxazolopyridine derivatives, processes for preparing these and pharmaceutical compositions containing them
EA200100553A1 (ru) Замещенные бициклические производные, полезные в качестве противораковых агентов
EA200000391A1 (ru) Производные тиенопиримидина и тиенопиридина, полезные в качестве противораковых агентов
SE9904508D0 (sv) New compounds
NO20045486L (no) Nye forbindelser og deres anvendelse
PT992509E (pt) Novos derivados macrolidos
NO20040589L (no) Arylsulfonylderivater med 5-HT6 reseptor affinitet.
SE0102055D0 (sv) New Compounds
CA2356985A1 (en) 5ht1 antagonists for antidepressant therapy
DE69600272D1 (de) Chinolin-4-carbonylguanidin-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
BR1101133A (pt) Derivado de sinergistina, (quinuclidinil-3(s) tiometil-5 bem como seus sais farmaceuticamente aceitáveis, processo de preparação do derivado de sinergistina e composição farmacêutica
BR0016937A (pt) Compostos tricìclicos e método de tratar herpesvìrus
DK0556813T3 (da) Amfotere tricykliske forbindelser som antihistaminske og antiallergiske midler
DE60234024D1 (de) Neue retinoidderivate und eine pharmazeutische anti-krebs-zusammensetzung, die diese verbindungen enthält
EA200100725A2 (ru) Новые бензотиадиазиновые соединения, способ их получения и их содержащие фармацевтические композиции
DE60227113D1 (de) Kondensierte camptothecine als antitumormittel
DE69908855D1 (de) 9a, 11b-dehydro Derivative von 9-oxime-3-keto-6-0-methylerythromycin
DE69400283T2 (de) (Cyclohexyl)alkenderivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
AR026682A1 (es) Compuesto de carbapenem, uso del mismo y de su compuesto intermediario